Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

[1]  J. Oldenburg,et al.  Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study , 2018, Blood.

[2]  J. Oldenburg,et al.  Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  H. Fukase,et al.  Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers , 2018, Clinical pharmacology in drug development.

[4]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.

[5]  J. Oldenburg,et al.  Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting , 2017 .

[6]  N. Kotani,et al.  A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A , 2017, Clinical Pharmacokinetics.

[7]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[8]  S. Frostick,et al.  Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  U. Scholz,et al.  Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH) , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  P. Giangrande,et al.  Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[11]  J. Oldenburg,et al.  Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  E. Santagostino,et al.  Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. , 2016, Blood.

[13]  K. Yoneyama,et al.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. , 2016, Blood.

[14]  J. Oldenburg,et al.  Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  K. Wyrwich,et al.  Interpreting important health‐related quality of life change using the Haem‐A‐QoL , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[17]  R. Ljung,et al.  The current status of prophylactic replacement therapy in children and adults with haemophilia , 2015, British journal of haematology.

[18]  J. Mahlangu,et al.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) , 2015, Journal of thrombosis and haemostasis : JTH.

[19]  J. Oldenburg,et al.  Prophylaxis in adult patients with severe haemophilia A. , 2014, Thrombosis research.

[20]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[21]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[22]  M. Franchini,et al.  Hemophilia A in the third millennium. , 2013, Blood reviews.

[23]  L. Prihodova,et al.  Haemophilia care in Europe – a survey of 35 countries , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  C. Witmer,et al.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence , 2013, Therapeutic advances in hematology.

[25]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  Tsukasa Suzuki,et al.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.

[27]  M. Skinner.  WFH: Closing the global gap – achieving optimal care , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[29]  T. Lambert,et al.  Prophylaxis in haemophilia with inhibitors: update from international experience , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  Y. Chatzizisis,et al.  The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. , 2007, European journal of internal medicine.

[31]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[32]  B. Evatt,et al.  Occurrence of hemophilia in the United States , 1998 .